« Back
Home /
BETd-246

BETd-246

Item no.	HY-115568-10mM
Manufacturer	MedChem Express
CASRN	2140289-17-2
Amount	10 mMx1 mL
Quantity options	100 mg 10 mMx1 mL 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.34
Citations	[1]Bai L, et al. Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. Cancer Res. 2017 May 1;77(9):2476-2487.
Smiles	O=C(C1=NC(NC2=CC(C3CC3)=NN2CC)=C4C(NC5=C4C=C(OC)C(C6=C(C)ON=C6C)=C5)=N1)NCCCOCCOCCOCCCNC7=CC=CC(C(N8C(CC9)C(NC9=O)=O)=O)=C7C8=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	2140289-17-2
Similar products	2140289-17-2
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Epigenetic Reader Domain; PROTACs
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, stored under nitrogen)
Molecular Weight	946.02
Product Description	BETd-246 is a second-generation and PROTAC-based BET bromodomain (BRD) inhibitor connected by ligands for Cereblon and BET, exhibiting superior selectivity, potency and antitumor activity[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 200 mg/mL (ultrasonic)
Manufacturer - Pathway	Epigenetics; PROTAC
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-115568-10mM-safety-datasheet.pdf